{ "id": 9, "date": "2026-07-31T17:22:03", "date_gmt": "2026-07-31T15:22:03", "guid": { "rendered": "https:\/\/abionbio.com\/?page_id=9" }, "modified": "2026-08-19T10:31:32", "modified_gmt": "2026-08-19T08:31:32", "slug": "pipeline", "status": "publish", "type": "page", "link": "http:\/\/abionbio.com\/en\/pipeline\/", "title": { "rendered": "Pipeline" }, "content": { "rendered": "

Our pipeline<\/h1>

Abion\u2019s drug discovery begins with the biological mechanisms that enable cancer to evade existing therapies and develop resistance.<\/p><\/header>

Assets<\/span>Target<\/span>Modality<\/span>Lead indication<\/span>Development stage<\/span><\/div>\n\t\t\t
<\/span>ABN202<\/strong><\/small><\/span>TROP2<\/span>IRAC<\/strong>Antibody\u2013interferon-\u03b2 fusion<\/small><\/span>Solid tumors after ADC failure<\/span><\/i><\/span>Preclinical, IND-enabling<\/small><\/span><\/summary>
\"\"

The lead iRAC candidate \u2014 a TROP2-directed antibody fused to interferon-\u03b2, designed for tumours that have progressed on ADC therapy.<\/p>

  • Overcoming the Limitations of ADCs<\/li>
  • Novel Mechanism of Action<\/li>
  • Validation of Preclinical Findings<\/li>
  • Validation of the Development Plan Through IND<\/li><\/ul><\/div><\/div><\/details>\n\t\t\t
    <\/span>ABN501<\/strong><\/small><\/span>Claudin-3<\/span>CLDN3<\/strong>Human monoclonal antibody, with ADC and bispecific formats<\/small><\/span>CLDN3-positive solid tumors including SCLC<\/span><\/i><\/span>Preclinical complete, out-licensed<\/small><\/span><\/summary>
    \"\"

    A first-in-class human antibody against claudin-3, a tight-junction protein overexpressed across solid tumours.<\/p>

    • Why CLDN3 Has Historically Been Overlooked<\/li>
    • Antibody characteristics and selectivity<\/li>
    • Monoclonal Antibody, ADC, and CLDN3\u00d7CD3 Bispecific Antibody<\/li>
    • Potential for Indication Expansion<\/li><\/ul><\/div><\/div><\/details>\n\t\t\t
      <\/span>ABN401<\/strong>Vabametkib<\/small><\/span>c-MET<\/span>Small molecule<\/strong>Oral small-molecule TKI<\/small><\/span>NSCLC with MET exon 14 skipping or MET amplification<\/span><\/i><\/span>Phase 2<\/small><\/span><\/summary>
      \"\"

      An oral, selective c-MET inhibitor in Phase 2 for NSCLC driven by MET exon 14 skipping and MET amplification.<\/p>

      • Challenges associated with c-MET<\/li>
      • Differentiating features of Vabametkib (selectivity, tolerability)<\/li>
      • Clinical program highlights<\/li>
      • Concurrent development of companion diagnostics<\/li><\/ul>\n\n\t
        \n\t\t

        PRIMARY ENDPOINT<\/p>\t\t

        55%<\/p>\n\t\t\t\t\t

        ORR<\/strong> (BICR-confirmed)
        \nNa\u00efve 50% \u00b7 Treated 60%<\/span><\/p>\n\t\t\t<\/article>\n\t\t

        \n\t\t

        DISEASE CONTROL<\/p>\t\t

        83%<\/p>\n\t\t\t\t\t

        DCR<\/strong> vs. ~80% for approved peers<\/span><\/p>\n\t\t\t<\/article>\n\t\t

        \n\t\t

        PROGRESSION-FREE<\/p>\t\t

        8.54mo<\/small><\/p>\n\t\t\t\t\t

        median PFS<\/strong> tepo 8.5 \u00b7 cap 6.7 \u00b7 savo 6.9<\/span><\/p>\n\t\t\t<\/article>\n\t\t

        \n\t\t

        DURABILITY \u2605<\/p>\t\t

        19.4mo<\/small><\/p>\n\t\t\t\t\t

        median DoR<\/strong> (na\u00efve) \u2014 longest reported in class<\/span><\/p>\n\t\t\t<\/article>\n\t<\/div><\/div><\/details>\n\t\t<\/div><\/div><\/section>", "protected": false }, "excerpt": { "rendered": "", "protected": false }, "author": 1, "featured_media": 0, "parent": 0, "menu_order": 0, "comment_status": "closed", "ping_status": "closed", "template": "page-pipeline.php", "meta": { "om_disable_all_campaigns": false, "footnotes": "" }, "class_list": [ "post-9", "page", "type-page", "status-publish", "hentry" ], "_links": { "self": [ { "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/pages\/9", "targetHints": { "allow": [ "GET" ] } } ], "collection": [ { "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/pages" } ], "about": [ { "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/types\/page" } ], "author": [ { "embeddable": true, "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/users\/1" } ], "replies": [ { "embeddable": true, "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/comments?post=9" } ], "version-history": [ { "count": 2, "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/pages\/9\/revisions" } ], "predecessor-version": [ { "id": 144, "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/pages\/9\/revisions\/144" } ], "wp:attachment": [ { "href": "http:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/media?parent=9" } ], "curies": [ { "name": "wp", "href": "https:\/\/api.w.org\/{rel}", "templated": true } ] } }